Althian mentioned as site participating in immuno-oncology lung cancer trial in the New England Journal of Medicine

Althian is proud to be an active clinical research site in oncology protocols. We have the experience of working with several treatments in oncology, such as oral drugs, chemotherapies, immunotherapies, and biosimilars.

We are very pleased to say that we have been mentioned as a participating clinical research site in the phase 3 CheckMate 227 Non-Small Cell Lung Cancer trial article in the New England Journal of Medicine published on April 16, 2018.

All the staff in Althian is highly motivated and certainly excited about this mention in the article. We continue with our commitment to work for our patients because we understand research is very important to generate information and be able to have new treatment options.

The reference for finding the article in the Journal is here:

Hellmann, M., Ciuleanu, T.-E., Pluzanski, A., Seok Lee, J., Otterson, G., Audigier-Valette, C., et. al.  (16 de April de 2018). Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. The New England Journal of Medicine.